RE:RE:Companies now seek to moderate TME to expand PD-(L)1 effectThis may not take as long as you might expect, given that ONCY has demonstrated (Aware-1 study) which predictive biomarkers can be used to determine which breast cancer patients and now which GI cancer patients can benefit from the I/O combination of pelareorep + PD-(L)1 through the current Bracelet-1 and Goblet Phase 2 studies. This has been explained throughout the clinical development process and Big Pharma is able to interpret the available results and may be waiting for a near-term event to execute on their M&A plans.